The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

These IgG-mediated alloimmune diseases show impaired core fucosylation of the Fc portion of maternal IgG antibodies. This has been associated with enhanced binding to FcγRIIIa receptors on effector ...

Recently, a new class of therapeutics that disable the neonatal Fc receptor (FcRn), which protects IgG from degradation, has emerged to treat IgG-mediated autoimmune disease. 4,5 Here, we review ...

NHS patients around the country are now receiving a lifesaving medicine made from the plasma of blood donors in ...

Nipocalimab effectively reduced maternal alloantibodies implicated in fetal and neonatal alloimmune thrombocytopenia (FNAIT) by targeting the neonatal Fc receptor (FcRn) and preventing pathogenic ...

Seismic Therapeutic Inc.'s S-1117 was designed as a pan-IgG protease fused to an effector function silent human IgG1 Fc domain. The candidate, being developed for the treatment of ...

The Low Affinity Immunoglobulin Gamma Fc Region Receptor III A pipeline drugs market research report outlays comprehensive information on the Low Affinity Immunoglobulin Gamma Fc Region Receptor III A ...

An Engineered IgG1 Monoclonal Antibody Targeting Plasma Kallikrein for the Prevention of HAE” at the 2022 Fc Receptor and IgG Targeted Therapies Conference which takes place April 26-28 in ...

Fc receptors (FcRs) are a group of glycoproteins that belong to the immunoglobulin superfamily and are classified, like Fc alpha receptors (FcαRs), Fc gamma receptors (FcγRs) and Fc epsilon ...